BioCardia Inc
BCDA
查看详细走势图
1.270USD
-0.010-0.78%
收盘 12/19, 16:00（美东）报价延迟15分钟
13.47M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.78%
5天
-12.41%
1月
-0.78%
6月
-38.94%
今年开始到现在
-41.74%
1年
-35.53%
查看详细走势图
TradingKey BioCardia Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
BioCardia Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名177/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价15.50。中期看，股价处于平稳状态。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
BioCardia Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
15.500
目标均价
+983.92%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
BioCardia Inc亮点
亮点风险
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
BioCardia Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
BioCardia Inc简介
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
公司代码BCDA
公司BioCardia Inc
CEOAltman (Peter)
网址https://www.biocardia.com/
常见问题
BioCardia Inc(BCDA)的当前股价是多少？
BioCardia Inc(BCDA)的当前股价是 1.270。
BioCardia Inc的股票代码是什么？
BioCardia Inc的股票代码是BCDA。
BioCardia Inc股票的52周最高点是多少？
BioCardia Inc股票的52周最高点是3.200。
BioCardia Inc股票的52周最低点是多少？
BioCardia Inc股票的52周最低点是1.000。
BioCardia Inc的市值是多少？
BioCardia Inc的市值是13.47M。
BioCardia Inc的净利润是多少？
BioCardia Inc的净利润为-7.95M。
现在BioCardia Inc(BCDA)的股票是买入、持有还是卖出？
根据分析师评级，BioCardia Inc(BCDA)的总体评级为买入，目标价格为15.500。
BioCardia Inc(BCDA)股票的每股收益（EPS TTM）是多少
BioCardia Inc(BCDA)股票的每股收益（EPS TTM）是-1.414。
相关品种
